WO2006067392A3 - Indole derivatives for the treatment of tuberculosis - Google Patents
Indole derivatives for the treatment of tuberculosis Download PDFInfo
- Publication number
- WO2006067392A3 WO2006067392A3 PCT/GB2005/004876 GB2005004876W WO2006067392A3 WO 2006067392 A3 WO2006067392 A3 WO 2006067392A3 GB 2005004876 W GB2005004876 W GB 2005004876W WO 2006067392 A3 WO2006067392 A3 WO 2006067392A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- tuberculosis
- indole derivatives
- medicament
- manufacture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007547617A JP2008525394A (en) | 2004-12-23 | 2005-12-16 | Compound |
EP05818623A EP1904487A2 (en) | 2004-12-23 | 2005-12-16 | Indole derivatives for the treatment of tuberculosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0428173.9A GB0428173D0 (en) | 2004-12-23 | 2004-12-23 | Compounds |
GB0428173.9 | 2004-12-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006067392A2 WO2006067392A2 (en) | 2006-06-29 |
WO2006067392A3 true WO2006067392A3 (en) | 2007-03-08 |
Family
ID=34113122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2005/004876 WO2006067392A2 (en) | 2004-12-23 | 2005-12-16 | Indole derivatives for the treatment of tuberculosis |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1904487A2 (en) |
JP (1) | JP2008525394A (en) |
CN (1) | CN101087781A (en) |
GB (1) | GB0428173D0 (en) |
WO (1) | WO2006067392A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7314732B2 (en) | 2000-02-17 | 2008-01-01 | Tfk Inc. | Drug and manufacturing method of same |
FR2967672B1 (en) * | 2010-11-22 | 2012-12-28 | Sanofi Aventis | NITROBENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATIONS THEREOF |
WO2013055674A1 (en) * | 2011-10-10 | 2013-04-18 | The University Of Toledo | Method for treating infections |
JP6223452B2 (en) * | 2012-09-07 | 2017-11-01 | ノバルティス アーゲー | Indole carboxamide derivatives and uses thereof |
PL3203840T3 (en) | 2014-10-06 | 2021-01-11 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US10738030B2 (en) | 2016-03-31 | 2020-08-11 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2018064632A1 (en) | 2016-09-30 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
WO2018107100A1 (en) | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
BR112019025801A2 (en) | 2017-06-08 | 2020-07-07 | Vertex Pharmaceuticals Incorporated | treatment methods for cystic fibrosis |
AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2019028228A1 (en) | 2017-08-02 | 2019-02-07 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
WO2019046467A1 (en) | 2017-08-29 | 2019-03-07 | Rutgers, The State University Of New Jersey | Therapeutic indazoles |
WO2019046465A2 (en) * | 2017-08-29 | 2019-03-07 | Rutgers, The State University Of New Jersey | Therapeutic indoles |
WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
AU2018380426B2 (en) | 2017-12-08 | 2023-05-18 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
TWI810243B (en) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | Pharmaceutical compositions for treating cystic fibrosis |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
EP4149459A1 (en) * | 2020-05-12 | 2023-03-22 | PMV Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02165131A (en) * | 1988-12-20 | 1990-06-26 | Konica Corp | Silver halide photographic sensitive material restrained from occurrence of fog |
EP0791582A1 (en) * | 1995-08-04 | 1997-08-27 | Otsuka Kagaku Kabushiki Kaisha | Indole-2-carboxylic ester derivatives and agricultural and horticultural bacteriocides containing the same as the active ingredient |
WO1999007351A2 (en) * | 1997-08-07 | 1999-02-18 | Zeneca Limited | Indole derivatives and their use as mcp-1 antagonists |
WO1999033800A1 (en) * | 1997-12-24 | 1999-07-08 | Aventis Pharma Deutschland Gmbh | Indole derivatives as inhibitors or factor xa |
WO2000046195A1 (en) * | 1999-02-05 | 2000-08-10 | Astrazeneca Ab | Anti-inflammatory indole derivatives |
US6352958B1 (en) * | 1997-02-26 | 2002-03-05 | Fmc Corporation | Cycloimido-substituted benzofused heterocyclic herbicides |
US6372752B1 (en) * | 2000-02-07 | 2002-04-16 | Genzyme Corporation | Inha inhibitors and methods of use thereof |
-
2004
- 2004-12-23 GB GBGB0428173.9A patent/GB0428173D0/en not_active Ceased
-
2005
- 2005-12-16 JP JP2007547617A patent/JP2008525394A/en active Pending
- 2005-12-16 EP EP05818623A patent/EP1904487A2/en not_active Withdrawn
- 2005-12-16 CN CNA2005800444016A patent/CN101087781A/en active Pending
- 2005-12-16 WO PCT/GB2005/004876 patent/WO2006067392A2/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02165131A (en) * | 1988-12-20 | 1990-06-26 | Konica Corp | Silver halide photographic sensitive material restrained from occurrence of fog |
EP0791582A1 (en) * | 1995-08-04 | 1997-08-27 | Otsuka Kagaku Kabushiki Kaisha | Indole-2-carboxylic ester derivatives and agricultural and horticultural bacteriocides containing the same as the active ingredient |
US6352958B1 (en) * | 1997-02-26 | 2002-03-05 | Fmc Corporation | Cycloimido-substituted benzofused heterocyclic herbicides |
WO1999007351A2 (en) * | 1997-08-07 | 1999-02-18 | Zeneca Limited | Indole derivatives and their use as mcp-1 antagonists |
US6441004B1 (en) * | 1997-08-07 | 2002-08-27 | Zeneca Limited | Monocyte chemoattractant protein-1 inhibitor compounds |
WO1999033800A1 (en) * | 1997-12-24 | 1999-07-08 | Aventis Pharma Deutschland Gmbh | Indole derivatives as inhibitors or factor xa |
WO2000046195A1 (en) * | 1999-02-05 | 2000-08-10 | Astrazeneca Ab | Anti-inflammatory indole derivatives |
US6372752B1 (en) * | 2000-02-07 | 2002-04-16 | Genzyme Corporation | Inha inhibitors and methods of use thereof |
Non-Patent Citations (5)
Title |
---|
BERTHOLD H ET AL: "Identification of cardiotonic sodium channel activators by potassium depolarization in isolated guinea-pig atria.", JOURNAL OF PHARMACOLOGICAL METHODS., vol. 24, no. 2, September 1990 (1990-09-01), pages 121 - 135, XP002393947, ISSN: 0160-5402 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, LEE JENG-JONG ET AL: "Catalysis of decarboxylation of 6-nitrobenzisoxazole-3-carboxylate by cationic polymer colloids", XP002393946, Database accession no. PREV199396083201 * |
JOURNAL OF ORGANIC CHEMISTRY, vol. 58, no. 15, 1993, pages 4070 - 4077, ISSN: 0022-3263 * |
KETTLE JASON G ET AL: "N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS., vol. 14, no. 2, 19 January 2004 (2004-01-19), pages 405 - 408, XP002393948, ISSN: 0960-894X * |
PATENT ABSTRACTS OF JAPAN vol. 014, no. 422 (P - 1104) 12 September 1990 (1990-09-12) * |
Also Published As
Publication number | Publication date |
---|---|
EP1904487A2 (en) | 2008-04-02 |
CN101087781A (en) | 2007-12-12 |
GB0428173D0 (en) | 2005-01-26 |
JP2008525394A (en) | 2008-07-17 |
WO2006067392A2 (en) | 2006-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006067392A3 (en) | Indole derivatives for the treatment of tuberculosis | |
WO2009054479A1 (en) | Spiro-ring compound and use thereof for medical purposes | |
WO2007087395A3 (en) | UNSATURATED mTOR INHIBITORS | |
WO2008075068A3 (en) | Acylaminopyrazoles as fgfr inhibitors | |
WO2008115516A8 (en) | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same | |
WO2007003962A3 (en) | Gpcr agonists | |
WO2007003961A3 (en) | Gpcr agonists | |
WO2007117465A3 (en) | Indazole compounds | |
WO2009017837A3 (en) | Sublingual fentanyl spray | |
WO2005110410A3 (en) | Kinase inhibitors as therapeutic agents | |
IL180916A0 (en) | Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | |
EP1864665A4 (en) | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | |
WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
MX2020008616A (en) | Sublingual fentanyl spray. | |
WO2008001101A3 (en) | Pharmaceutical combinations | |
WO2008120725A1 (en) | Novel pyrrolinone derivative and medicinal composition containing the same | |
WO2005021544A3 (en) | N3-substituted imidazopyridine-derivatives as c-kit inhibitors | |
EP1714961A4 (en) | Indazole compound and pharmaceutical use thereof | |
WO2008008660A3 (en) | Cyclopentane derivatives as antiglaucoma agents | |
UA96304C2 (en) | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | |
WO2007112913A3 (en) | Benzimidazole derivatives | |
WO2008004100A9 (en) | Therapeutic compounds | |
WO2008093838A1 (en) | Pyridyl imidazolidine derivative having sulfamoyl group, and pharmaceutical use thereof | |
WO2007140136A3 (en) | Therapeutic cyclopentane derivatives | |
MX2008002063A (en) | Pyrazolone derivatives for the treatment of tuberculosis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005818623 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007547617 Country of ref document: JP Ref document number: 200580044401.6 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 05818623 Country of ref document: EP Kind code of ref document: A2 |
|
WWP | Wipo information: published in national office |
Ref document number: 2005818623 Country of ref document: EP |